PDB108 Treatment Patterns and Health Care Resource Utilization of Patients with Acromegaly in the United States  by Chuang, C.C. et al.
A450  VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  
analysis of phase III registration trials (full-publication if available, and Clinical 
Trial report/study Synopsis) and EPARs of commonly used short-acting (Insulin 
Aspart and Insulin Glulisine) and pre-mix (Biphasic Insulin Aspart) insulin ana-
logues. Results: Therapy adjustments based on SMBG data were documented 
in 5/24 Insulin Aspart-, 3/18 Insulin Glulisine- and 4/15 Biphasic Insulin Aspart 
phase III registration trials. The EPARs of all three insulin analogues recommend 
the use of SMBG to adjust the insulin doses, repeatedly and throughout all sections 
in EPAR. ConClusions: Overall, in 12/57 phase III registration trials the dose of 
insulin analogues was regularly adjusted based on SMBG data, and the EPARs of all 
insulin analogues explicitly recommend the use of SMBG to adjust the insulin doses. 
Therefore, the demonstrated safety and efficacy of these insulin analogues are the 
result of a complex intervention including insulin analogues, their dose adjust-
ments based on SMBG data as well as training rather than the insulin analogues 
alone. This is not consequently reflected in reimbursement schemes, in particular 
in emerging countries. Full study reports were not available for further analysis. 
These potentially would have provided deeper insights on how SMBG was used in 
the remaining 45/57 trials.
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objeCtives: Little is known about routine use of basal insulins (Glargine, Detemir, 
NPH) in primary care patients with type 2 diabetes. The aim was to compare 
injection frequencies of basal insulins in type 2 diabetes (T2D) in primary care 
practices, both for basal-supported oral (BOT) and basal-bolus (ICT) treatment regi-
mens. Methods: Primary care data from 4,503 Glargine (BOT/ICT: 2,247/1,964), 
1,373 Detemir (490/800), and 4,072 NPH-insulin (1,331/2,425) users were retrospec-
tively analysed (05/2009-04/2012). The Disease Analyzer database (IMS HEALTH) 
assembles drug prescriptions, diagnoses, basic medical and demographic data 
obtained from the practice computer system of general practitioners and special-
ists throughout Germany. The Charlson Comorbidity Index was used as generic 
marker of comorbidity. Logistic regression (> 1 daily injection) and propensitiy scores 
were used to adjust for various confounders (age, sex, type of physician, dosage, 
BMI, HbA1c). Results: Overall, more than one daily injections were observed in 
7.5% of Glargine users (BOT: 6.2%, ICT: 9.0%), which was lower than for Detemir 
(overall: 25.4%; BOT: 22.0%, ICT: 27.4%) and NPH-insulin (25.4%; BOT: 23.9%, ICT: 
27.2%) (all p< 0.001). The adjusted odds of having more than one injection was lower 
for Glargine compared to Detemir (OR; 95% CI: 0.26; 0.22-0.32) and NPH-insulin 
(0.20; 0.17-0.23). Similar results were found for BOT (Glargine vs. Detemir: 0.23; 
0.17-0.32; Glargine vs. NPH-insulin: 0.16; 0.13-0.21) and for ICT (Glargine vs. Detemir: 
0.27; 0.21-0.35; Glargine vs. NPH-insulin: 0.22; 0.18-0.27). Finally, after matching the 
groups for the propensity score, the odds for more than one daily injection was also 
significantly reduced in the Glargine group both compared to Detemir (OR; 95%CI: 
0.30; 0.24-0.37) and NPH insulin (0.25; 0.22-0.29). ConClusions: Glargine is associ-
ated with significant lower injection frequencies than other basal insulins. These 
findings might impact treatment satisfaction and as a consequence quality of life, 
persistence and economic aspects of diabetes treatment.
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objeCtives: To examine treatment intensification and switching patterns of 
individuals with T2DM initiating OHM. The results are compared to international 
guidelines issued in 2009. Methods: Data were analysed using a population-based 
pharmacy claims database from January 2008 to November 2012. Incident users of 
OHM were identified for 2008-2009 as not having received OHM in the previous 12 
months. Patients dispensed insulin, > one OHM, or < 16 years were excluded from 
the study. Patients were followed until Nov-2012. Treatment intensification was 
defined as receiving an additional one, or two hypoglycaemic medicines (double or 
triple-therapy respectively). Treatment switching was defined as OHM monotherapy 
discontinuation with initiation on alternative monotherapy. Results: A total of 
24,869 patients were included in the study. Most were initiated on metformin (76.4%) 
or sulphonylureas (21.6%). Treatment intensification: 25.8% of patients initiated 
on metformin progressed to double-therapy. Sulphonylureas (61.5%), DPP-4 inhibi-
tors (23.9%) and GLP-1 agonists (6.2%) were the most frequently prescribed add-on 
treatment (median time to add-on OHM= 424days). Of those initiated on sulpho-
nylureas 32.4% progressed to double-therapy; metformin (78.4%), DPP-4 inhibitors 
(9.3%) and long-acting insulin (5%) were the most frequently prescribed (median 
time to add-on= 295days). 14.3% of patients on double-therapy progressed to triple-
therapy (median time to add-on= 434days). 26.6% of patients did not receive the 
recommended double-therapy and 64.3% received agents in their triple-therapy 
that were not recommended. Treatment Switching: Overall 7.1% switched medi-
cation. The most frequent switches were metformin to sulphonylureas (46.5%, 
median time to switch= 226days), sulphonylureas to metformin (22.5%, median 
time to switch= 330days) and metformin to DPP-4 inhibitors (6.9%, median time 
to switch= 577days). Initial OHM was significantly associated with time to switch 
(p< .0001). ConClusions: Initial drug treatment followed guidelines. However, 
evidence-based practice was not closely followed for treatment intensification 
suggesting prescribers may be unaware of treatment guidelines. This data may be 
useful for assessing the potential place in therapy, and cost-effectiveness of new 
hypoglycaemic medicines.
carry financial burden, impact patients’ daily functioning and well-being and may 
be serious obstacles to optimal diabetes control. This burden may be some lower in 
Germany than other countries.
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objeCtives: To examine patient characteristics, treatment patterns, and health 
care resource utilization of patients with acromegaly in the US. Methods: Using 
a large US claims database, adult individuals with commercial insurance newly 
diagnosed with acromegaly (ICD-9-CM: 253.0) between 07/01/2007 and 12/31/2010 
were identified (the first observed diagnosis was the index date). Patients were 
required to have 6-month pre-index and 12-month post-index continuous enroll-
ment. Descriptive analysis was performed to describe demographic and clini-
cal characteristics, treatment patterns of acromegaly, and health care resource 
utilization during the post-index period. Similar analysis was conducted for 
Medicare-eligible patients with supplemental private insurance. Results: This 
study included 930 commercially-insured patients (mean age: 47.2 years; 52.0% 
female) and 104 Medicare-eligible patients (mean age: 72.8 years; 36.5% female) 
with acromegaly. For the commercial population, of the comorbidities evaluated, 
hypertension (38.2%), diabetes (25.9%), and anthropathy/arthralgia/synovitis 
(23.7%) had the highest prevalence. More than half of the patients (57.3%) received 
no treatment; 21.7% received tumor resection surgery and 21.0% received medi-
cal therapy as the first-line treatment. During the 12-month post-index period, 
one-third had inpatient hospitalization and 23.2% had emergency room visit; 
the mean physician office visit was 17.1. For the Medicare population, hyperten-
sion (67.3%), diabetes (36.5%), and anthropathy/arthralgia/synovitis (29.8%) were 
most prevalent comorbidities. About two-thirds (63.5%) received no treatment; 
8.7% received tumor resection surgery and 27.9% received medical therapy 
as the first-line treatment. More than one-third (34.6%) had inpatient hospitaliza-
tion and 26.9% had emergency room visit during the 12-month post-index period; 
the mean physician office visit was 21.1. ConClusions: Our findings suggest 
high unmet needs in the population with more than half of patients with acro-
megaly being untreated. Efforts should be made to understand this untreated 
population to provide better care. Future research should investigate different 
treatment options as well as their impact on health care costs and health care 
resource utilization.
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objeCtives: HbA1c concentrations predict the risk of complications in patients 
with type 2 diabetes mellitus (T2DM). This study assessed temporal trends in ele-
vated HbA1c levels in the UK primary care setting. Methods: T2DM was identi-
fied by medical diagnosis, prescribing, elevated blood glucose and/or prescribing of 
monitoring devices. Patients had ≥ 12 months of CPRD history, with data available 
for the entire year of observation. T2DM patients prescribed insulin were excluded. 
Mean HbA1c levels and proportion of patients with elevated HbA1c were assessed 
across six years (01/04/2006–31/03/2012). Elevated HbA1c was defined according to 
the UK Quality and Outcomes Framework (QOF) threshold: > 7.5% for all years except 
2009/2010 (> 7.0%). Estimates were stratified by age-band, gender, T2DM-status and 
treatment categories. Results: Mean HbA1c levels among 176,428 patients were 
relatively stable and below threshold across the study period (2006/2007: 7.05%; 
2011/2012: 7.16%), with the exception of 2009/2010 (7.09%). Nonetheless, > 20% of 
patients had a record of elevated HbA1c in each year (36.7% in 2009/2010). Elevations 
were more common among males than females (20%-25.0% vs. 18%-20%) and among 
patients 40-59 years (27.2%-33.7 %) vs. those ≥ 60 years (15.9%-23.3%). Although 
elevations were similar among prevalent (20%-23%) and incident-T2DM (22%-23%), 
prevalent-T2DM showed an increasing trend in the proportions with an elevation 
over time, whilst incident-T2DM showed a decreasing trend. The proportion with 
elevated HbA1c varied by treatment: diet and exercise 4.8%-6.1%; monotherapy 24%; 
dual therapy 32.7%-38.0%, and; triple therapy 42%-50%. Over 80% of patients with 
elevated HbA1c were overweight or obese, > 20% had a 10-year Framingham Risk 
score > 20% (patients without existing CVD) and 17%-21% of patients had history of 
chronic renal failure. ConClusions: Although mean HbA1c concentrations were 
below target (apart from 2009/2010), elevated HbA1c was present in > 20% patients 
across all years. Further efforts are needed to help patients to achieve adequate 
glycaemic control.
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objeCtives: Registration trials’ purpose is to show safety and efficacy of insulin 
therapy. They are the basis of subsequent insulin reimbursement decisions. Insulin 
dosing is typically individualized: a safe and efficacious insulin therapy requires 
upfront dose finding and regular dose adjustments. These adjustments are based 
on data from Self-Monitoring of Blood Glucose (SMBG). However, some countries 
reimburse insulin analogues, but not blood glucose test strips. This analysis inves-
tigates the use of SMBG in Phase III registration trials of selected insulin analogues 
and if consequently the European Public Assessment Reports (EPARs) recommend 
the use of SMBG as part of the insulin therapy. Methods: Systematic search and 
